NYSE:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis $0.53 +0.03 (+5.12%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends About NovaBay Pharmaceuticals Stock (NYSE:NBY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NBY alerts:Sign Up Key Stats Today's Range$0.50▼$0.5350-Day Range$0.49▼$0.7852-Week Range$0.36▼$9.10Volume580,562 shsAverage Volume903,055 shsMarket Capitalization$2.60 millionP/E RatioN/ADividend YieldN/APrice Target$0.85Consensus RatingBuy Company OverviewNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Read More… NovaBay Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks29th Percentile Overall ScoreNBY MarketRank™: NovaBay Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNovaBay Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about NovaBay Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovaBay Pharmaceuticals has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NBY. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovaBay Pharmaceuticals does not currently pay a dividend.Dividend GrowthNovaBay Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NBY. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for NovaBay Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows4 people have added NovaBay Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of NovaBay Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 23.25% of the stock of NovaBay Pharmaceuticals is held by institutions.Read more about NovaBay Pharmaceuticals' insider trading history. Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NBY Stock News HeadlinesNovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of StockholdersDecember 19 at 6:50 AM | businesswire.comNovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special MeetingDecember 9, 2024 | businesswire.comWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.December 22, 2024 | Behind the Markets (Ad)NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024November 22, 2024 | businesswire.comNovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase PriceNovember 6, 2024 | businesswire.comNovaBay Pharmaceuticals To Sell Assets Of Its Avenova Brand - Quick FactsSeptember 21, 2024 | markets.businessinsider.comNBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.'s Avenova Brand and Business Is Fair to ShareholdersSeptember 20, 2024 | businesswire.comAcumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay PharmaceuticalsSeptember 20, 2024 | finance.yahoo.comSee More Headlines NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed this year? NovaBay Pharmaceuticals' stock was trading at $7.14 on January 1st, 2024. Since then, NBY shares have decreased by 92.6% and is now trading at $0.5299. View the best growth stocks for 2024 here. When did NovaBay Pharmaceuticals' stock split? NovaBay Pharmaceuticals's stock reverse split on the morning of Friday, May 31st 2024. The 1-35 reverse split was announced on Friday, May 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Adverum Biotechnologies (ADVM), American Resources (AREC), Clearside Biomedical (CLSD), Hello Group (MOMO), Palatin Technologies (PTN), Xeris Biopharma (XERS) and Algonquin Power & Utilities (AQN). Company Calendar Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NBY CUSIPN/A CIK1389545 Webnovabay.com Phone510-899-8800Fax510-474-1577Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$0.85 High Stock Price Target$0.85 Low Stock Price Target$0.85 Potential Upside/Downside+60.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($53.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,640,000.00 Net Margins-102.72% Pretax Margin-99.12% Return on Equity-7,293.78% Return on Assets-158.41% Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio0.91 Sales & Book Value Annual Sales$13.84 million Price / Sales0.19 Cash FlowN/A Price / Cash FlowN/A Book Value$4.25 per share Price / Book0.12Miscellaneous Outstanding Shares4,908,000Free Float4,903,000Market Cap$2.60 million OptionableNot Optionable Beta0.69 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NYSE:NBY) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.